KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy.
Ghimessy AK, Gellert A, Schlegl E, Hegedus B, Raso E, Barbai T, Timar J, Ostoros G, Megyesfalvi Z, Gieszer B, Moldvay J, Renyi-Vamos F, Lohinai Z, Hoda MA, Klikovits T, Klepetko W, Laszlo V, Dome B.
Ghimessy AK, et al. Among authors: ostoros g.
Cancers (Basel). 2019 Oct 9;11(10):1514. doi: 10.3390/cancers11101514.
Cancers (Basel). 2019.
PMID: 31600989
Free PMC article.